Glucotrack, INC 10-K annual reports

Glucotrack, Inc. reports progress on its implantable continuous blood glucose monitor and recent financing, but faces substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing challenges.

Glucotrack Inc.'s latest 10-K filing highlights the company's focus on developing its implantable continuous blood glucose monitor (CBGM) while navigating financial uncertainties and Nasdaq compliance.

GlucoTrack, Inc.'s 2023 annual report highlights a strategic shift towards implantable continuous glucose monitoring (CGM) technology, alongside ongoing financial losses and concerns about the company's ability to continue as a going concern.